Market Overview

ACADIA Pharma Shares Move Higher as JMP Boosted Price Target from $16 to $27

Related ACAD
ACADIA Pharmaceuticals Announces Stephen Davis As Executive VP, CFO And Chief Business Officer
4 Biotech Stocks Worth A Look Ahead Of FDA Approvals

JMP Securities maintains ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) with a Market Outperform and raises the price target from $16.00 to $27.00.

The stock has opened up more than 4 percent higher. With the stock last trading at $19.45, the firm's new price target implies potential upside of about 39 percent.

Posted-In: News Price Target Analyst Ratings

 

Most Popular

Related Articles (ACAD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters